Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs)
$47.40
pos +0.40
+0.85%
Today's Range: 45.81 - 47.55 | BMY Avg Daily Volume: 10,421,400
Last Update: 05/24/13 - 4:00 PM EDT
Volume: 12,605,344
YTD Performance: 45.44%
Open: $46.56
Previous Close: $47.00
52 Week Range: $30.64 - $47.48
Oustanding Shares: 1,642,551,939
Market Cap: 77,199,941,133
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 1 1 1 1
Hold 12 13 13 12
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.45 2.48 2.48 2.45
Latest Dividend: 0.35
Latest Dividend Yield: 2.98%
Dividend Ex-Date: 04/03/13
Price Earnings Ratio: 52.81
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
52.81 54.00 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
28.46% 43.68% 106.18%
GROWTH 12 Mo 3 Yr CAGR
Revenue -17.10 -0.06 -0.02
Net Income -52.50 -0.43 -0.17
EPS -46.30 -0.78 -0.39
Earnings for BMY:
EBITDA 4.77B
Revenue 17.62B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $0.45 $0.46 $1.81 $2.13
Number of Analysts 9 8 12 10
High Estimate $0.47 $0.48 $1.85 $2.42
Low Estimate $0.43 $0.44 $1.78 $1.93
Prior Year $0.48 $0.37 $1.99 $1.81
Growth Rate (Year over Year) -6.94% 24.32% -9.17% 17.73%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Esoptions
Esoptions: $bmy One of the most bullish charts on liquid US equities
3 hours ago from web
BeFullyInformed
BeFullyInformed: $BMY rescue strategy on stock caught with deep in the money covered calls http://t.co/qsTl1RZveG
4 hours ago from web
sstrella
sstrella: RT @brucejapsen: Obamacare Will Bring Drug Industry $35 Billion In Profits - Forbes http://t.co/mT1Mm5IuIJ #ACA #Obamacare $ABT $PFE $LLY $BMY $ABBV $JNJ
5 hours ago from Falcon Pro
GantosJ
GantosJ: RT @brucejapsen Obamacare Will Bring Drug Industry $35B In Profits http://t.co/cUPhNZIm6l #ACA #Obamacare $ABT $PFE $LLY $BMY $ABBV $JNJ
6 hours ago from TweetDeck
MilionCapital
MilionCapital: Weekly Options Making New 52 Wk Highs Today: $BA, $BMY, $IOC, $PG, $TSLA
6 hours ago from StockTwits Web
brucejapsen
brucejapsen: Obamacare Will Bring Drug Industry $35 Billion In Profits - Forbes http://t.co/mT1Mm5IuIJ #ACA #Obamacare $ABT $PFE $LLY $BMY $ABBV $JNJ
6 hours ago from Tweet Button
GantosJ
GantosJ: @kokurasluck Congrats Sam keep it up... This was awesome trade $BMY gave us a nice return.. We had a perfect entry point
15 hours ago from Mobile Web (M5)
bio20006
bio20006: RT @evaluatepharma: Upcoming #pharma events: May 27 – June 2 http://t.co/i0Le2aNZSU $RHHBY $HALO $DEPO $MRK $GILD $BMY
22 hours ago from web
evaluatepharma
evaluatepharma: Upcoming #pharma events: May 27 – June 2 http://t.co/i0Le2aNZSU $RHHBY $HALO $DEPO $MRK $GILD $BMY
23 hours ago from HootSuite
GantosJ
GantosJ: $BMY printed today a new 52 weeks high $47.55 ..had a 20% run bouncing from the 50MA ..but our Options X4 & 3 times
1 day ago from web
Update
UBS Healthcare Conf.
May 21, 2013 | 6:44 AM EDT
UBS Global Healthcare Conference
Bullish
Bristol-Myers upgraded at Leerink
May 17, 2013 | 8:18 AM EDT
BMY was upgraded from Market Perform to Outperform, Leerink Swann said. Cancer product pipeline should drive future growth. 
Biotech's Next Big Thing -- ASCO II

Biotech's Next Big Thing -- ASCO II

By

Adam Feuerstein

May 16, 2013 | 2:09 PM EDT
Bullish
Bristol-Myers target boosted at Goldman
May 16, 2013 | 8:15 AM EDT
Shares of BMY now seen reaching $48, according to Goldman Sachs. PD-1 data has exceeded expectations. Buy rating. 
Biotech's Next Big Thing: ASCO

Biotech's Next Big Thing: ASCO

By

Adam Feuerstein

May 09, 2013 | 9:39 AM EDT
Update
BMY Investor Mtg.
May 07, 2013 | 7:07 AM EDT
 Bristol-Myers Squibb Annual Shareholder Meeting - 10AM

Tackling the Rotation Dilemma

By

Jim Cramer

| May 07, 2013 | 6:53 AM EDT
I have always resolved it in a practical, but chicken, way.

It's Pipeline That Matters Most

By

Jim Cramer

| May 01, 2013 | 12:49 PM EDT
Focusing on near-term drug stock earnings is the wrong move.
Bearish
Bristol-Myers estimates reduced at Leerink
Apr 29, 2013 | 8:28 AM EDT
BMY estimates were cut through 2014, Leerink Swann said. Company is seeing lower Eliquis sales. Market Perform rating.

National Lemming Day

By

Jim Cramer

| Apr 24, 2013 | 1:16 PM EDT
It’s the only thing that explains today’s action.

Columnist Conversation / Market Updates

Easy Money (Part One)
By Doug Kass
| May 25, 2013
| 8:45 AM EDT
"It's the lure of easy money. It has a very strong appeal." -Glenn Frey, Smuggler's Blues Investors bor...
SPX cash daily chart
By Carolyn Boroden
| May 24, 2013
| 3:24 PM EDT
There is no technical damage on the daily chart of $SPX at this point. Actually this decline is only similar to prior d...
See all »

Our Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.